| Name | SGLT2 Inhibitors for Parkinson's Disease |
| Summary | SGLT2 inhibitor therapy for Parkinson's disease - empagliflozin, dapagliflozin clinical trials, mechanisms, and neuroprotective evidence |
| Key Genes/Proteins | MTOR, mTOR, VDAC1, HK2 |
| Related Diseases | type 2 diabetes, neurodegeneration, Parkinson's disease |
| Related Pathways | ferroptosis, oxidative stress response, lipid metabolism, senescence |